pioglitazone has been researched along with Dementia in 15 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of pioglitazone was compared with that of other second-line glucose-lowering drugs on the risk of dementia among individuals with type 2 diabetes receiving metformin-based dual therapy." | 7.88 | Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. ( Hsieh, CY; Li, CY; Lu, CH; Ou, HT; Yang, CY, 2018) |
| " Therefore, in this population-based cohort study, we investigated the effects of pioglitazone, a PPAR-γ agonist, on the risk of dementia." | 7.85 | Effects of pioglitazone on the incidence of dementia in patients with diabetes. ( Chou, PS; Ho, BL; Yang, YH, 2017) |
| "Using observational data from 2004-2010, we analyzed the association of pioglitazone and incidence of dementia in a prospective cohort study of 145,928 subjects aged ≥60 years who, at baseline, were free of dementia and insulin-dependent diabetes mellitus." | 7.81 | Effect of pioglitazone medication on the incidence of dementia. ( Doblhammer, G; Fink, A; Heneka, MT, 2015) |
| "The present study was undertaken to investigate possible mechanism of pioglitazone-induced beneficial effect in memory deficits associated with experimental dementia." | 7.75 | Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. ( Jaggi, AS; Kaur, B; Singh, N, 2009) |
| "The prevalence of type 2 diabetes (T2DM) in elderly people has expanded rapidly." | 5.91 | Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study. ( Jenq, CC; Lee, CC; Li, YJ; Liu, JR; Liu, YC; Peng, WS; See, LC; Tsai, CY; Wu, CY; Yang, HY; Yen, CL, 2023) |
| "Pioglitazone is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist and is widely used to treat type 2 diabetes." | 5.51 | Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus. ( Cha, BS; Kang, ES; Kim, E; Lee, BW; Lee, HC; Lee, M; Lee, PH; Lee, YH; Moon, JH; Seok, H; Shin, E; Yun, MR, 2019) |
| "The effect of pioglitazone was compared with that of other second-line glucose-lowering drugs on the risk of dementia among individuals with type 2 diabetes receiving metformin-based dual therapy." | 3.88 | Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. ( Hsieh, CY; Li, CY; Lu, CH; Ou, HT; Yang, CY, 2018) |
| " Therefore, in this population-based cohort study, we investigated the effects of pioglitazone, a PPAR-γ agonist, on the risk of dementia." | 3.85 | Effects of pioglitazone on the incidence of dementia in patients with diabetes. ( Chou, PS; Ho, BL; Yang, YH, 2017) |
| "Using observational data from 2004-2010, we analyzed the association of pioglitazone and incidence of dementia in a prospective cohort study of 145,928 subjects aged ≥60 years who, at baseline, were free of dementia and insulin-dependent diabetes mellitus." | 3.81 | Effect of pioglitazone medication on the incidence of dementia. ( Doblhammer, G; Fink, A; Heneka, MT, 2015) |
| "The present study was undertaken to investigate possible mechanism of pioglitazone-induced beneficial effect in memory deficits associated with experimental dementia." | 3.75 | Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. ( Jaggi, AS; Kaur, B; Singh, N, 2009) |
| "Pioglitazone (AD4833) is an insulin sensitizer of the thiazolidinedione class of nuclear Peroxisome-Proliferator Activated Receptor γ (PPARγ) agonists." | 2.55 | Pioglitazone for the treatment of Alzheimer's disease. ( Galimberti, D; Scarpini, E, 2017) |
| "The prevalence of type 2 diabetes (T2DM) in elderly people has expanded rapidly." | 1.91 | Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study. ( Jenq, CC; Lee, CC; Li, YJ; Liu, JR; Liu, YC; Peng, WS; See, LC; Tsai, CY; Wu, CY; Yang, HY; Yen, CL, 2023) |
| "Pioglitazone is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist and is widely used to treat type 2 diabetes." | 1.51 | Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus. ( Cha, BS; Kang, ES; Kim, E; Lee, BW; Lee, HC; Lee, M; Lee, PH; Lee, YH; Moon, JH; Seok, H; Shin, E; Yun, MR, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Maxwell, CJ | 1 |
| Alkabbani, W | 1 |
| Yasar, S | 1 |
| Yen, CL | 1 |
| Wu, CY | 1 |
| Tsai, CY | 1 |
| Lee, CC | 1 |
| Li, YJ | 1 |
| Peng, WS | 1 |
| Liu, JR | 1 |
| Liu, YC | 1 |
| Jenq, CC | 1 |
| Yang, HY | 1 |
| See, LC | 1 |
| Feng, Q | 1 |
| Lewis, A | 1 |
| Galetta, S | 1 |
| Kim, E | 2 |
| Lu, CH | 1 |
| Yang, CY | 1 |
| Li, CY | 1 |
| Hsieh, CY | 1 |
| Ou, HT | 1 |
| Pantoni, L | 1 |
| Seok, H | 1 |
| Lee, M | 1 |
| Shin, E | 1 |
| Yun, MR | 1 |
| Lee, YH | 1 |
| Moon, JH | 1 |
| Lee, PH | 1 |
| Lee, BW | 1 |
| Kang, ES | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Heneka, MT | 1 |
| Fink, A | 1 |
| Doblhammer, G | 1 |
| Jain, S | 1 |
| Sharma, B | 1 |
| Galimberti, D | 1 |
| Scarpini, E | 1 |
| Chou, PS | 1 |
| Ho, BL | 1 |
| Yang, YH | 1 |
| Kaur, B | 1 |
| Singh, N | 1 |
| Jaggi, AS | 1 |
| Araki, A | 1 |
| Pathan, AR | 1 |
| Viswanad, B | 1 |
| Sonkusare, SK | 1 |
| Ramarao, P | 1 |
2 reviews available for pioglitazone and Dementia
| Article | Year |
|---|---|
Pioglitazone for the treatment of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Cognition; Dementia; Disease Progression; Humans; Hypoglycemic Age | 2017 |
[Dementia and insulin resistance in patients with diabetes mellitus].
Topics: Animals; Dementia; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Piogl | 2010 |
13 other studies available for pioglitazone and Dementia
| Article | Year |
|---|---|
Pioglitazone and Lower Risk of Dementia: Will This Change Practice?
Topics: Dementia; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk | 2023 |
Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Dementia; Diabetes Mellitus, Type 2; Fractures, Bone; | 2023 |
Reader Response: Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
Topics: Dementia; Diabetes Mellitus; Humans; Ischemic Stroke; Patients; Pioglitazone | 2023 |
Editors' Note: Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
Topics: Dementia; Diabetes Mellitus; Humans; Ischemic Stroke; Patients; Pioglitazone | 2023 |
Author Response: Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
Topics: Dementia; Diabetes Mellitus; Humans; Ischemic Stroke; Patients; Pioglitazone | 2023 |
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
Topics: Aged; Dementia; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; L | 2018 |
Potential New Horizons for the Prevention of Cerebrovascular Diseases and Dementia.
Topics: Cerebrovascular Disorders; Dementia; Humans; Pioglitazone; Prediabetic State; Stroke | 2019 |
Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus.
Topics: Amyloid beta-Peptides; Animals; Dementia; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; | 2019 |
Effect of pioglitazone medication on the incidence of dementia.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Dementia; Diabetes Mellitus; Female; | 2015 |
Effect of ruthenium red, a ryanodine receptor antagonist in experimental diabetes induced vascular endothelial dysfunction and associated dementia in rats.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Brain; Calcium Channel Blockers; Dementia; Diabetes Mell | 2016 |
Effects of pioglitazone on the incidence of dementia in patients with diabetes.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Dementia; Diabetes Mellitus, Type 2; Dose-Resp | 2017 |
Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia.
Topics: Acetylcholinesterase; Animals; Blood Glucose; Brain; Dementia; Disease Models, Animal; Glutathione; | 2009 |
Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats.
Topics: Administration, Oral; Aging; Animals; Antibiotics, Antineoplastic; Brain Chemistry; Cognition; Demen | 2006 |